Thioether-based Semi-permeable Polymer Vesicle for <italic style="font-style: italic">In situ</italic> Scavenging of H<sub>2</sub>O<sub>2</sub> during Hyperuricemia Treatment with Urate Oxidase

Chun Yang; Tong Wu; Min Sun; Zhen Fan; Jian-Zhong Du

doi:10.1007/s10118-026-3847-7

Your Location：

Home >

Browse articles >

Thioether-based Semi-permeable Polymer Vesicle for In situ Scavenging of H₂O₂ during Hyperuricemia Treatment with Urate Oxidase

RESEARCH ARTICLE | Updated：2026-10-23

- Thioether-based Semi-permeable Polymer Vesicle for In situ Scavenging of H₂O₂ during Hyperuricemia Treatment with Urate Oxidase
- Chinese Journal of Polymer Science Vol. 44, Pages: 1-10(2026)
- Affiliations：
  
  a.Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai 201804, China
  b.School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China
- Author bio：
  
  Minsun2025@ecust.edu.cn (M.S.)
  fanzhen2018@tongji.edu.cn (Z.F.)
  jzdu@tongji.edu.cn (J.Z.D.)
- Funds：
- DOI：10.1007/s10118-026-3847-7
  CLC：
- Received：26 June 2026，
  
  Accepted：15 August 2026，
  
  Online First：22 October 2026，
  
  Published：2026-09
- Accepted：
Scan QR Code
Yang, C.; Wu, T.; Sun, M.; Fan, Z.; Du, J. Z. Thioether-based semi-permeable polymer vesicle for in situ scavenging of H₂O₂ during hyperuricemia treatment with urate oxidase. Chinese J. Polym. Sci. https://doi.org/10.1007/s10118-026-3847-7

Chun Yang, Tong Wu, Min Sun, et al. Thioether-based Semi-permeable Polymer Vesicle for In situ Scavenging of H₂O₂ during Hyperuricemia Treatment with Urate Oxidase[J/OL]. Chinese Journal of Polymer Science, 2026, 441-10. DOI: 10.1007/s10118-026-3847-7.
Yang, C.; Wu, T.; Sun, M.; Fan, Z.; Du, J. Z. Thioether-based semi-permeable polymer vesicle for in situ scavenging of H₂O₂ during hyperuricemia treatment with urate oxidase. Chinese J. Polym. Sci. https://doi.org/10.1007/s10118-026-3847-7 DOI：

Chun Yang, Tong Wu, Min Sun, et al. Thioether-based Semi-permeable Polymer Vesicle for In situ Scavenging of H₂O₂ during Hyperuricemia Treatment with Urate Oxidase[J/OL]. Chinese Journal of Polymer Science, 2026, 441-10. DOI: 10.1007/s10118-026-3847-7. DOI：

摘要

Abstract

Hyperuricemia is a major risk factor for gout

renal injury

and cardiovascular disease

necessitating effective control of serum uric acid levels. Existing therapies face challenges such as limited efficacy

renal toxicity

and dosing complexities. Urate oxidase (UOx) offers a potent enzymatic degradation strategy but suffers from

in vivo

persistence

immunogenicity

and the generation of the harmful byproduct hydrogen peroxide (H

)

which limits its clinical utility. Here we report a dual-functional polymeric vesicle that functions as a microreactor for UOx delivery. The vesicular membrane was designed to reduce the direct exposure of encapsulated UOx to immune components

while thioether groups embedded within the membrane rapidly scavenge H

generated

in situ

. This integrated design enables simultaneous uric acid degradation and byproduct elimination without introducing additional enzymes. UOx@vesicle retained 78.1% of the enzymatic activity of free UOx. In hyperuricemic mice

UOx@vesicle maintained a significant uric acid-lowering effect for up to 73 h

approximately 2 days longer than free UOx

while attenuating immune responses and decreasing serum biochemical markers associated with hepatic and renal dysfunction. This work provides a general strategy for enhancing the safety and efficacy of enzyme-based therapeutics for hyperuricemia and other reactive oxygen species-related diseases.

关键词

Keywords

references

[Management of gout. N. Engl. J. Med . 1996, 334 , 1543−1544..

Bardin, T.; Richette, P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017 , 15 , 123..

Sato, Y.; Feig, D. I.; Stack, A. G.; Kang, D. H.; Lanaspa, M. A.; Ejaz, A. A.; Sánchez-Lozada, L. G.; Kuwabara, M.; Borghi, C.; Johnson, R. J. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat. Rev. Nephrol. 2019 , 15 , 767−775..

Major, T. J.; Dalbeth, N.; Stahl, E. A.; Merriman, T. R. An update on the genetics of hyperuricaemia and gout. Nat. Rev. Rheumatol. 2018 , 14 , 341−353..

So, A. K.; Martinon, F. Inflammation in gout: mechanisms and therapeutic targets. Nat. Rev. Rheumatol. 2017 , 13 , 639−647..

Dehlin, M.; Jacobsson, L.; Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 2020 , 16 , 380−390..

Maiuolo, J.; Oppedisano, F.; Gratteri, S.; Muscoli, C.; Mollace, V. Regulation of uric acid metabolism and excretion. Int. J. Cardiol. 2016 , 213 , 8−14..

Pantakitcharoenkul, J.; Mekkhayai, K.; Paengkhumpung, K.; Asgharpour, A.; Coblyn, M.; Pornputtapitak, W.; Jovanovic, G.; Jangpatarapongsa, K. Parametric evaluation of hy brid hydrogel-based colorimetric assay for rapid quantitative analysis of uric acid. Eng. Sci. 2025 , 34 , 1398..

Sima, Y.; Chen, A.; Jiang, Y.; Liu, N.; Ding, J.; Zhang, T.; Wan, K.; Xiang, H.; Wang, W.; He, Q. Sensitive and simultaneous determination of epinephrine, uric acid and folic acid in biological fluids using a novel nickel-cobalt metal-organic framework and multi-walled carbon nanotubes electrochemical sensor. Eng. Sci. 2026 , 41 , 2184..

Yang, C. Y.; Chen, C. H.; Deng, S. T.; Huang, C. S.; Lin, Y. J.; Chen, Y. J.; Wu, C. Y.; Hung, S. I.; Chung, W. H. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in taiwan. JAMA Intern. Med. 2015 , 175 , 1550−1557..

Hung, S. I.; Chung, W. H.; Liou, L. B.; Chu, C. C.; Lin, M.; Huang, H. P.; Lin, Y. L.; Lan, J. L.; Yang, L. C.; Hong, H. S.; Chen, M. J.; Lai, P. C.; Wu, M. S.; Chu, C. Y.; Wang, K. H.; Chen, C. H.; Fann, C. S. J.; Wu, J.-Y.; Chen, Y. T. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. 2005 , 102 , 4134−4139..

Ng, C. Y.; Yeh, Y. T.; Wang, C. W.; Hung, S. I.; Yang, C. H.; Chang, Y. C.; Chang, W. C.; Lin, Y., Jr.; Chang, C. J.; Su, S. C.; Fan, W. L.; Chen, D. Y.; Wu, Y. J. J.; Tian, Y. C.; Hui, R. C. Y.; Chung, W. H. Impact of the HLA-B*58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J. Invest. Dermatol. 2016 , 136 , 1373−1381..

[Richette, P.; Doherty, M.; Pascual, E.; Barskova, V.; Becce, F.; Castañeda-Sanabria, J.; Coyfish, M.; Guillo, S.; Jansen, T. L.; Janssens, H.; Lioté, F.; Mallen, C.; Nuki, G.; Perez-Ruiz, F.; Pimentao, J.; Punzi, L.; Pywell, T.; So, A.; Tausche, A. K.; Uhlig, T.; Zavada, J.; Zhang, W.; Tubach, F.; Bardin, T. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis . 2017, 76 , 29−42..

Lv, M.; Xu, J.; Chen, R.; Hu, W.; Zhou, Y.; Sun, M.; Fan, Z.; Du, J. Albumin corona-coated nanoscale metal–organic framework for enzyme-mediated cascade metabolization of uric acid in hyperuricemia. Small 2025 , 21 , 2412612..

Oldfield, V.; Perry, C. M. Rasburicase. Drugs 2006 , 66 , 529−545..

Ramazzina, I.; Folli, C.; Secchi, A.; Berni, R.; Percudani, R. Completing the uric acid degradation pathway through phylogenetic comparison of whole genomes. Nat. Chem. Biol. 2006 , 2 , 144−148..

Yang, X.; Yuan, Y.; Zhan, C.-G.; Liao, F. Uricases as therapeutic agents to treat refractory gout: current states and future directions. Drug Dev. Res. 2012 , 73 , 66−72..

Scomparin, A.; Florindo, H. F.; Tiram, G.; Ferguson, E. L.; Satchi-Fainaro, R. Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. Adv. Drug Delivery Rev. 2017 , 118 , 52−64..

Cortes, J.; Moore, J. O.; Maziarz, R. T.; Wetzler, M.; Craig, M.; Matous, J.; Luger, S.; Dey, B. R.; Schiller, G. J.; Pham, D.; Abboud, C. N.; Krishnamurthy, M.; Brown, A.; Laadem, A.; Seiter, K. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J. Clin. Oncol. 2010 , 28 , 4207−4213..

Sundy, J. S.; Baraf, H. S. B.; Yood, R. A.; Edwards, N. L.; Gutierrez-Urena, S. R.; Treadwell, E. L.; Vázquez-Mellado, J.; White, W. B.; Lipsky, P. E.; Horowitz, Z.; Huang, W.; Maroli, A. N.; Waltrip, R. W., II; Hamburger, S. A.; Becker, M. A. Efficacy and tolerability of pegloticase for the treatment of c hronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011 , 306 , 711−720..

Yin, L.; Yuvienco, C.; Montclare, J. K. Protein based therapeutic delivery agents: Contemporary developments and challenges. Biomaterials 2017 , 134 , 91−116..

Sathish, J. G.; Sethu, S.; Bielsky, M.-C.; de Haan, L.; French, N. S.; Govindappa, K.; Green, J.; Griffiths, C. E. M.; Holgate, S.; Jones, D.; Kimber, I.; Moggs, J.; Naisbitt, D. J.; Pirmohamed, M.; Reichmann, G.; Sims, J.; Subramanyam, M.; Todd, M. D.; Van Der Laan, J. W.; Weaver, R. J.; Park, B. K. Challenges and approaches for the development of safer immunomodulatory biologics. Nat. Rev. Drug Discovery 2013 , 12 , 306−324..

Schlesinger, N.; Pérez-Ruiz, F.; Lioté, F. Mechanisms and rationale for uricase use in patients with gout. Nat. Rev. Rheumatol. 2023 , 19 , 640−649..

Ibrahim, M.; Ramadan, E.; Elsadek, N. E.; Emam, S. E.; Shimizu, T.; Ando, H.; Ishima, Y.; Elgarhy, O. H.; Sarhan, H. A.; Hussein, A. K.; Ishida, T. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J. Control. Release 2022 , 351 , 215− 230..

[Kozma, G. T.; Shimizu, T.; Ishida, T.; Szebeni, J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv. Drug Delivery Rev . 2020, 154−155 , 163−175..

Fu, J.; Wu, E.; Li, G.; Wang, B.; Zhan, C. Anti-PEG antibodies: Current situation and countermeasures. Nano Today 2024 , 55 , 102163..

Caliceti, P.; Schiavon, O.; Veronese, F. M. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjugate Chem. 2001 , 12 , 515−522..

Pasut, G.; Veronese, F. M. State of the art in PEGylation: The great versatility achieved after forty years of research. J. Control. Release 2012 , 161 , 461−472..

Tian, H.; Guo, Y.; Gao, X.; Yao, W. PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation. J. Pharm. Pharmacol. 2013 , 65 , 53−63..

[Hershfield, M. S.; Sundy, J. S.; Ganson, N. J.; Kelly, S. J., Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout. In PEGylated protein drugs: basic science and clinical applications , Veronese, F. M., Ed. Birkhäuser Basel: Basel, 2009 , pp. 217-227..

Hu, X.; Wang, Y.; Liu, C.; Jin, Z.; Tian, Y. Dextrin-uricase conjugate: preparation, characterization, and enzymatic properties. Int. J. Biol. Macromol. 2018 , 111 , 28−32..

Ming, J.; Zhu, T.; Li, J.; Ye, Z.; Shi, C.; Guo, Z.; Wang, J.; Chen, X.; Zheng, N. A novel cascade nanoreactor integrating two-dimensional Pd-Ru nanozyme, uricase and red blood cell membrane for highly efficient hyperuricemia treatment. Small 2021 , 17 , 2103645..

Millán, C. G.; Marinero, M. a. L. S.; Castañeda, A. Z.; Lanao, J. M. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control. Release 2004 , 95 , 27−49..

Tan, Q. Y.; Wang, N.; Yang, H.; Zhang, L. K.; Liu, S.; Chen, L.; Liu, J.; Zhang, L.; Hu, N. N.; Zhao, C. J.; Zhang, J. Q. Characterization, stabilization and activit y of uricase loaded in lipid vesicles. Int. J. Pharm. 2010 , 384 , 165−172..

Tan, Q.; Zhang, J.; Wang, N.; Li, X.; Xiong, H.; Teng, Y.; He, D.; Wu, J.; Zhao, C.; Yin, H.; Zhang, L. Uricase from Bacillus fastidious loaded in alkaline enzymosomes: enhanced biochemical and pharmacological characteristics in hypouricemic rats. Eur. J. Pharm. Biopharm. 2012 , 82 , 43−48..

Xiong, H.; Zhou, Y.; Zhou, Q.; He, D.; Deng, X.; Sun, Q.; Zhang, J. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia. Nanomed. Nanotechnol. Biol. Med. 2016 , 12 , 1557−1566..

Yang, L.; Zhang, Y.; Xie, J.; Zhong, C.; He, D.; Wang, T.; Li, K.; Li, Y.; Shi, D.; Abagyan, R.; Yang, L.; Zhang, J. Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment. Nanoscale 2020 , 12 , 15222−15235..

Luk, B. T.; Fang, R. H.; Hu, C.-M. J.; Copp, J. A.; Thamphiwatana, S.; Dehaini, D.; Gao, W.; Zhang, K.; Li, S.; Zhang, L. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 2016 , 6 , 1004−1011..

Sands, E.; Kivitz, A.; DeHaan, W.; Leung, S. S.; Johnston, L.; Kishimoto, T. K. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat. Commun. 2022 , 13 , 272..

Tran, L.; Das, S.; Zhao, L.; Finn, M. G.; Gaucher, E. A. Oral delivery of nanoparticles carrying ancestral uricase enzyme protects against hyperuricemia in knockout mice. Biomacromolecules 2023 , 24 , 2003−2008..

Ban, Z.; Sun, M.; Ji, H.; Ning, Q.; Cheng, C.; Shi, T.; He, M.; Chen, X.; Lu, H.; He, X.; Guo, C.; He, Y.; Shao, D.; He, Y. Immunogenicity-masking delivery of uricase against hyperuricemia and gout. J. Control. Release 2024 , 372 , 862−873..

Li, Z.; Xue, L.; Yang, J.; Wuttke, S.; He, P.; Lei, C.; Yang, H.; Zhou, L.; Cao, J.; Sinelshchikova, A.; Zheng, G.; Guo, J.; Lin, J.; Lei, Q.; Brinker, C. J.; Liu, K.; Zhu, W. Synthetic biohybrids of red blood cells and cascaded-enzymes@ metal–organic frameworks for hyperuricemia treatment. Adv. Sci. 2024 , 11 , 2305126..

Liu, L.; Li, X .; Chen, Y.; Gao, J.; Jiang, Y.; Ye, Y.; Wang, P.; Peng, F.; Tu, Y. Gout management using uricase and sodium citrate hollow mesoporous nanomotors. Nat. Commun. 2025 , 16 , 2339..

Lin, A.; Sun, Z.; Xu, X.; Zhao, S.; Li, J.; Sun, H.; Wang, Q.; Jiang, Q.; Wei, H.; Shi, D. Self-cascade uricase/catalase mimics alleviate acute gout. Nano Lett. 2022 , 22 , 508−516..

Yang, B.; Luo, G.; Nie, T.; Ban, Z.; Ning, Q.; Zhang, J.; Liu, X.; Lin, Y.; Xie, X.; Chen, Q.; Zhong, H.; Huang, Y.; Liao, P.; Liu, Y.; Guo, C.; Cheng, C.; Sun, E. Biomimetic bioreactor for potentiated uricase replacement therapy in hyperuricemia and gout. Front. Bioeng. Biotechnol. 2025 , 12 , 1520663..

Hu, J.; Zhao, R.; Gu, J.; Xi, Z.; Wang, Y.; Sun, X.; Xu, Z.; Sha, K.; Xi, J.; Liu, Y.; Han, J.; Guo, R. Crystal facet controlled metal–support interaction in uricase mimics for highly efficient hyperuricemia treatment. Nano Lett. 2024 , 24 , 6634−6643..

Zhang, T.; Hong, B.; Liang, Y. Microfluidic approaches in extracellular vesicle engineering: recent advances for enhanced therapeutic efficacy. Eng. Sci. 2026 , 39 , 2013..

[Musa, A.; Abdjan, M. I.; Aminah, N. S.; Kristanti, A. N.; Sanjaya, I. G. M.; Wardana, A. P.; Balah, S. S.; Takaya, Y. α-Glucosidase enzyme inhibitors from Shorea beccariana, pharmacokinetic and mechanism insights through in vitro and in silico studies. ES Food Agrofor . 2025, 20 , 1537..

Siswanto, I.; Abdjan, M. I.; Aminah, N. S.; Kristanti, A. N.; Rakhman, K. A.; Sanjaya, I. G. M.; Muggundha, R. s. o. R.; Takaya, Y. Drug design: indole derivatives as indoleamine 2,3-dioxygenase-1 enzyme inhibition using in silico approach. ES Food Agrofor. 2025 , 20 , 1496..

Abdjan, M. I.; Aminah, N. S.; Kristanti, A. N.; Siswanto, I.; Windah, A. L. L.; Thant, T. M.; Ramadhan, R.; Takaya, Y.; Ul-Haq, Z. U.; Choudhary, M. I. Computational studies on carbazole-pyranocoumarin conjugate against α-glucosidase enzyme. Eng. Sci. 2024 , 31 , 1286..

Gaitzsch, J.; Hirschi, S.; Freimann, S.; Fotiadis, D.; Meier, W. Directed insertion of light-activated proteorhodopsin into asymmetric polymersomes from an ABC block copolymer. Nano Lett. 2019 , 19 , 2503−2508..

Zhuan g, M.; Zhang, Y.; Zhou, S.; Zhang, Y.; Wang, K.; Nie, J.; Liu, J. Uricase-containing coacervate microdroplets as enzyme active membrane-free protocells for detoxification of uric acid in serum. Chem. Commun. 2019 , 55 , 13880−13883..

Belluati, A.; Craciun, I.; Liu, J.; Palivan, C. G. Nanoscale enzymatic compartments in tandem support cascade reactions in vitro. Biomacromolecules 2018 , 19 , 4023−4033..

Wu, D.; Rigo, S.; Di Leone, S.; Belluati, A.; Constable, E. C.; Housecroft, C. E.; Palivan, C. G. Brushing the surface: cascade reactions between immobilized nanoreactors. Nanoscale 2020 , 12 , 1551−1562..

Zhang, Z.; Gu, Y.; Liu, Q.; Zheng, C.; Xu, L.; An,Y.; Jin, X.; Liu, Y.; Shi, L. Spatial confined synergistic enzymes with enhanced uricolytic performance and reduced toxicity for effective gout treatment. Small 2018 , 14 , 1801865..

Gupta, M. K.; Meyer, T. A.; Nelson, C. E.; Duvall, C. L. Poly(PS-b-DMA) micelles for reactive oxygen species triggered drug release. J. Control. Release 2012 , 162 , 591−598..

Yoo, D.; Magsam, A. W.; Kelly, A. M.; Stayton, P. S.; Kievit, F. M.; Convertine, A. J. Core-cross-linked nanoparticles reduce neuroinflammation and improve outcome in a mouse model of traumatic brain injury. ACS Nano 2017 , 11 , 8600−8611..

Tarudji, A. W.; Gee, C. C.; Romereim, S. M.; Convertine, A. J.; Kievit, F. M. Antioxidant thioether core-crosslinked nanoparticles prevent the bilateral spread of secondary injury to protect spatial learning and memory in a controlled cortical impact mouse model of traumatic brain injury. Biomaterials 2021 , 272 , 120766..

Wollenberg, A. L.; O'Shea, T. M.; Kim, J. H.; Czechanski, A.; Reinholdt, L. G.; Sofroniew,M. V.; Deming, T. J. Injectable polypeptide hydrogels via methionine modification for neural stem cell delivery. Biomaterials 2018 , 178 , 527−545..

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Boosting Blood-Brain Barrier Crossing with a Mannosylated Nanocarrier

Antioxidant Glycopolypeptide Micelles for Targeted Delivery of Silibinin to Hepatocellular Carcinoma Cells

Interfacial Frustration-induced Novel Self-assembled Structures from Block Copolymers under Janus Spherical Confinement

End-group and Side-chain Dual-engineering of Selenium-fused Acceptors for 20.08% Efficiency Polymer Solar Cells with Low Energy Loss

Porous Organic Polymers for Photocatalytic Hydrogen Peroxide Production: Recent Advances and Future Perspectives

Related Author

Nan-Nan Gu

Ping Wei

Jin-Hui Jiang

Jing-Hua Chen

Kai Chen

Ping Wei

Jing-Hua Chen

Xing-Ye Li

Related Institution

School of Life Sciences and Health Engineering, Jiangnan University

Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University

Key Laboratory of Weak-Light Nonlinear Photonics, Ministry of Education, School of Physics, Nankai University

State Key Laboratory of Supramolecular Structure and Materials, Institute of Theoretical Chemistry, Jilin University

College of Chemistry, Zhengzhou University

⁰

Thioether-based Semi-permeable Polymer Vesicle for In situ Scavenging of H2O2 during Hyperuricemia Treatment with Urate Oxidase

DOI：10.1007/s10118-026-3847-7

摘要

Abstract

关键词

Keywords

references

Thioether-based Semi-permeable Polymer Vesicle for In situ Scavenging of H₂O₂ during Hyperuricemia Treatment with Urate Oxidase